Key result
Preoperative antithrombin activity was not associated with major adverse cardiac events after CABG surgery (0.91 vs 0.92 IU/mL; P=0.18), but postoperative activity was associated with MACE.
Why the study?
Is perioperative antithrombin activity independently associated with postoperative major adverse cardiac events in patients undergoing CABG surgery?
Cohort (n=1,403)
Is perioperative antithrombin activity independently associated with postoperative major adverse cardiac events in patients undergoing CABG surgery?
p-value: p=0.18
Preoperative antithrombin activity is not associated with MACE after CABG surgery, and while postoperative antithrombin activity is associated with MACE, it predominantly occurs after the event.
Postoperative AT activity may flag higher MACE risk after CABG; leaves open whether repletion improves outcomes.
BACKGROUND: Low levels of antithrombin (AT) have been independently associated with prolonged intensive care unit stay and an increased incidence of neurologic and thromboembolic events after cardiac surgery. We hypothesized that perioperative AT activity is independently associated with postoperative major adverse cardiac events (MACEs) in patients undergoing coronary artery bypass graft (CABG) surgery. METHODS: We prospectively studied 1403 patients undergoing primary CABG surgery with cardiopulmonary bypass (CPB) (http://clinicaltrials.gov/show/NCT00281164). The primary clinical end point was occurrence of MACE, defined as a composite outcome of any one or more of the following: postoperative death, reoperation for coronary graft occlusion, myocardial infarction, stroke, pulmonary embolism, or cardiac arrest until first hospital discharge. Plasma AT activity was measured before surgery, after post-CPB protamine, and on postoperative days (PODs) 1-5. Multivariate logistic regression modeling was performed to estimate the independent effect of perioperative AT activity upon MACE. RESULTS: MACE occurred in 146 patients (10.4%), consisting of postoperative mortality (n = 12), myocardial infarction (n = 108), stroke (n = 17), pulmonary embolism (n = 8), cardiac arrest (n = 16), or a subsequent postoperative or catheter-based treatment for graft occlusion (n = 6). AT activity at baseline did not differ between patients with (0.91 ± 0.13 IU/mL; n = 146) and without (0.92 ± 0.13 IU/mL; n = 1257) (P = 0.18) MACE. AT activity in both groups was markedly reduced immediately after CPB and recovered to baseline values over the ensuing 5 PODs. Postoperative AT activity was significantly lower in patients with MACE than those without MACE. After adjustment for clinical predictors of MACE, AT activity on PODs 2 and 3 was associated with MACE. CONCLUSIONS: Preoperative AT activity is not associated with MACE after CABG surgery. MACE is independently associated with postoperative AT activity but only at time points occurring predominantly after the MACE.
No takes yet. Share an insight, caveat, or question.
Garvin et al. (2010) conducted a cohort in Coronary artery bypass graft (CABG) surgery (n=1,403). Perioperative antithrombin (AT) activity was evaluated on Major adverse cardiac events (MACE), defined as postoperative death, reoperation for coronary graft occlusion, myocardial infarction, stroke, pulmonary embolism, or cardiac arrest (p=0.18). Preoperative antithrombin activity was not associated with major adverse cardiac events after CABG surgery (0.91 vs 0.92 IU/mL; P=0.18), but postoperative activity was associated with MACE.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: